scholarly journals The Influence of the Exclusion of Central Necrosis on [18F]FDG PET Radiomic Analysis

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1296
Author(s):  
Wyanne A. Noortman ◽  
Dennis Vriens ◽  
Charlotte D. Y. Mooij ◽  
Cornelis H. Slump ◽  
Erik H. Aarntzen ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Multiple Testing ◽  
Characteristic Curve ◽  
Tracer Uptake ◽  
Multiple Testing Correction ◽  
Central Necrosis ◽  
18F Fdg ◽  
Feature Values ◽  
Fdg Pet Ct ◽  
The Impact

Background: Central necrosis can be detected on [18F]FDG PET/CT as a region with little to no tracer uptake. Currently, there is no consensus regarding the inclusion of regions of central necrosis during volume of interest (VOI) delineation for radiomic analysis. The aim of this study was to assess how central necrosis affects radiomic analysis in PET. Methods: Forty-three patients, either with non-small cell lung carcinomas (NSCLC, n = 12) or with pheochromocytomas or paragangliomas (PPGL, n = 31), were included retrospectively. VOIs were delineated with and without central necrosis. From all VOIs, 105 radiomic features were extracted. Differences in radiomic features between delineation methods were assessed using a paired t-test with Benjamini–Hochberg multiple testing correction. In the PPGL cohort, performances of the radiomic models to predict the noradrenergic biochemical profile were assessed by comparing the areas under the receiver operating characteristic curve (AUC) for both delineation methods. Results: At least 65% of the features showed significant differences between VOIvital-tumour and VOIgross-tumour (65%, 79% and 82% for the NSCLC, PPGL and combined cohort, respectively). The AUCs of the radiomic models were not significantly different between delineation methods. Conclusion: In both tumour types, almost two-third of the features were affected, demonstrating that the impact of whether or not to include central necrosis in the VOI on the radiomic feature values is significant. Nevertheless, predictive performances of both delineation methods were comparable. We recommend that radiomic studies should report whether or not central necrosis was included during delineation.

scholarly journals The Impact of 18F-FDG-PET/CT in Esophageal Cancer

2019 ◽  
Vol 19 (2) ◽  
pp. 15-23
Author(s):  
Deif, D ◽  
Moustafa, H
Keyword(s):  
Esophageal Cancer ◽  
Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Impact

Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent

2021 ◽  
Vol 60 (06) ◽  
pp. 411-416
Author(s):  
Sheima Farag ◽  
Nikki S. IJzerman ◽  
Matthijs P.M. Houdijk ◽  
An K.L. Reyners ◽  
Anne IJ Arens ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Metabolic Response ◽  
Early Response ◽  
Ct Scans ◽  
Palliative Intent ◽  
Metastatic Gist ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Impact

Abstract Aim The aim of this study was to investigate the impact of 18F-FDG-PET/CT on treatment decision making in metastatic gastrointestinal stromal tumor (GIST) patients. Methods This study retrospectively evaluated 18F-FDG-PET/CT scans to monitor response of metastatic GIST patients treated with palliative intent. Data from the Dutch GIST Registry was used. Early scans (<10 weeks after start of treatment) and late scans (>10 weeks after start of treatment) were scored on the impact in change of treatment. Results Sixty-one PET/CT scans were performed for treatment evaluation in 39 patients with metastatic GIST of which 36 were early scans and 25 were late scans. Early PET/CT scans led to a change in management in 5.6% of patients and late PET/CT scans led to a change in management in 56% of patients. Change in management was more often seen after scans with lack of metabolic response (48% vs. 11% in scans with metabolic response, p=0.002). Neither metabolic response nor change in treatment were more often seen in patients with KIT mutations compared to patients with non-KIT mutations (metabolic response 65% KIT vs. 46% non-KIT, p=0.33, and change in management 28% KIT vs. 21% non-KIT, p=0.74). Conclusion 18F-FDG-PET/CT is not recommended for early response evaluation in an unselected patient population with metastatic GIST, since it does not influence treatment decisions. 18F-FDG-PET/CT, however, can be useful for late response assessment, especially in case of indeterminate CT results.

scholarly journals Additional Value of 2-[18F]FDG PET/CT Comparing to MRI in Treatment Approach of Anal Cancer Patients

2020 ◽  
Vol 9 (9) ◽  
pp. 2715
Author(s):  
Reyhaneh Manafi-Farid ◽  
Alexander Kupferthaler ◽  
Helwig Wundsam ◽  
Georg Gruber ◽  
Reza Vali ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Anal Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Number Of Patients ◽  
Pet Ct ◽  
18F Fdg ◽  
Pre Treatment ◽  
Fdg Pet Ct ◽  
The Impact

Accurate staging and treatment planning are imperative for precise management in Anal Cancer (ACa) patients. We aimed to evaluate the additive and prognostic value of pre-treatment 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (2-[18F]FDG PET/CT) in the staging and management of ACa compared to magnetic resonance imaging (MRI). This retrospective study was conducted on 54 patients. Pre-treatment 2-[18F]FDG PET/CT studies and MRI reports were compared considering the primary tumor, pelvic lymph nodes, and metastatic lesions. The impact of 2-[18F]FDG PET/CT in the management and its prognostic value, using maximum standardized uptake value (SUVmax), were assessed. Discordant findings were found in 46.3% of patients (5 in T; 1 in T and N; 18 in N; and 1 in M stage). 2-[18F]FDG PET/CT resulted in up-staging in 9.26% and down-staging in 3.7% of patients. Perirectal lymph nodes were metabolically inactive in 12.9% of patients. Moreover, 2-[18F]FDG PET/CT resulted in management change in 24.1% of patients. Finally, SUVmax provided no prognostic value. 2-[18F]FDG PET/CT altered staging and management in a sizable number of patients in this study, and supports a need for a change in guidelines for it to be used as a routine complementary test in the initial management of ACa.

Diagnostic value and therapeutic impact of 18F-FDG-PET/CT in differentiated thyroid cancer

2013 ◽  
Vol 52 (01) ◽  
pp. 1-6 ◽  
Author(s):  
M. Dietlein ◽  
D. Schmidt ◽  
T. Kuwert ◽  
R. Dorn ◽  
J. Sciuk ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Fdg Pet ◽  
Differentiated Thyroid Cancer ◽  
Tumour Tissue ◽  
Therapeutic Management ◽  
Whole Body ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Impact

SummaryThe clinical significance of 18F-FDG-PET/CT in the follow-up of patients with differentiated thyroid carcinoma was evaluated and the results were compared with those of 18F-FDGPET, 131I-whole-body scintigraphy including SPECT/CT (WBS) and ultrasound. In addition, it was the aim to investigate the impact of 18F-FDG-PET/CT on the therapeutic management. Patients, methods: 327 patients (209 women, 118 men; mean age 53 ± 18 years) with differentiated thyroid cancer (242 papillary, 75 follicular, 6 mixed, 1 Hürthle cell and 3 poorly differentiated tumours) were analyzed retrospectively at four tertiary referral centres. 289 18F-FDG-PET/CT and 118 18F-FDG-PET studies were performed in these patients between 2007 and 2010. In addition, an overall clinical evaluation was performed, including cytology, histology, thyroglobulin level, ultrasound, WBS, and subsequent clinical course in order to compare the molecular imaging results. Finally, the change in therapeutic management due to findings of 18F-FDG-PET/CT was investigated. Results: The sensitivity of 18F-FDG-PET/CT was 92%, the specificity was 95%. Sensitivity and specificity of 18F-FDG-PET alone were 67% and 93%, respectively. WBS showed a sensitivity of 65% and a specificity of 94%. The corresponding values of ultrasound were 37% and 94%, respectively. The sensitivity of 18F-FDG-PET/CT in the group of patients with a negative WBS (n=194) amounted to 96%. When 18F-FDG-PET/CT and WBS were considered in combination, tumour tissue was missed in only 2 out of 133 patients; when 18F-FDG-PET and WBS were combined, tumour tissue was missed in 1 out of 24 patients. 18F-FDG-PET/CT resulted in management change in 43% (n=57/133) with a decision on surgical approach in 20% (n=27/133). Conclusions: 18F-FDG-PET/CT is superior to 18F-FDG-PET alone in patients with differentiated thyroid cancer and has a direct impact on the therapeutic management of patients with suspected local recurrence or metastases, particularly in those with negative WBS.

scholarly journals Glucose Loading Enhances the Value of 18F-FDG PET/CT for the Characterization and Delineation of Cerebral Gliomas

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1977
Author(s):  
Dongwoo Kim ◽  
Hae Young Ko ◽  
Sangwon Lee ◽  
Yong-ho Lee ◽  
Sujin Ryu ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Characteristic Curve ◽  
Low Grade ◽  
High Grade ◽  
Glucose Loading ◽  
Pet Ct ◽  
Significant Difference ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Normal Cortex

This study aimed to assess how to enhance the value of 18F-Fluorodeoxyglucose (FDG) PET/CTs for glioma grading and better delineation of the tumor boundary by glucose loading. In mouse models of brain tumor using U87MG cells, 18F-FDG-PET images were obtained after fasting and after glucose loading. There was a significant difference in the tumor-to-normal cortex-uptake ratio (TNR) between the fasting and glucose-loading scans. 14C-2-Deoxy-D-glucose (14C-DG) uptake was measured in vitro using U87MG, U373MG and primary neurons cultured with different concentrations of glucose. The tumor-to-neuron ratio of 14C-DG uptake increased with up to 10 mM of glucose. Finally, 10 low-grade and 17 high-grade glioma patients underwent fasting and glucose loading 18F-FDG PET/CT and the TNR was compared between scans. The effect of glucose loading was significant in high-grade but not in low-grade gliomas. The receiver operating characteristic curve analyses with a cut-off TNR of 0.81 showed a higher area under the curve after glucose loading than fasting for differentiating low-grade versus high-grade gliomas. In addition, the glucose loading PET/CT was more useful than the fasting PET/CT for the discrimination of oligodendrogliomas from IDH-wildtype glioblastomas. Glucose loading resulted in a greater reduction in 18F-FDG uptake in the normal cortex than in tumors, which increases the usefulness of 18F-FDG PET/CT for grading.

scholarly journals Is integrated 18F-FDG PET/MRI superior to 18F-FDG PET/CT in the differentiation of incidental tracer uptake in the head and neck area?

2017 ◽  
Vol 23 (2) ◽  
pp. 127-132 ◽  
Author(s):  
Benedikt Michael Schaarschmidt ◽  
Benedikt Gomez ◽  
Christian Buchbender ◽  
Johannes Grueneisen ◽  
Felix Nensa ◽  
...  
Keyword(s):  
Head And Neck ◽  
Fdg Pet ◽  
Tracer Uptake ◽  
Pet Ct ◽  
Neck Area ◽  
18F Fdg ◽  
Fdg Pet Ct

The impact of 18F-FDG-PET/CT on Merkel cell carcinoma management

2014 ◽  
Vol 35 (3) ◽  
pp. 282-290 ◽  
Author(s):  
Adeline George ◽  
Sylvie Girault ◽  
Aude Testard ◽  
Rémy Delva ◽  
Patrick Soulié ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Fdg Pet ◽  
Merkel Cell ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Impact

The Impact of a Bayesian Penalized Likelihood Reconstruction Algorithm on the Evaluation of Indeterminate Pulmonary Nodules by Dual–Time Point 18F-FDG PET/CT

2017 ◽  
Vol 42 (7) ◽  
pp. e352-e354 ◽  
Author(s):  
Tiago Sampaio Vieira ◽  
Diogo Borges Faria ◽  
Fernando Azevedo Silva ◽  
Francisco Pimentel ◽  
José Pereira de Oliveira
Keyword(s):  
Fdg Pet ◽  
Penalized Likelihood ◽  
Pulmonary Nodules ◽  
Reconstruction Algorithm ◽  
Pet Ct ◽  
18F Fdg ◽  
Dual Time Point ◽  
Fdg Pet Ct ◽  
The Impact ◽  
Time Point
Sign in / Sign up

Export Citation Format

Share Document